Rgenta Therapeutics
Rgenta Therapeutics is developing a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders.
$52M Series A ·
Led by AstraZeneca · Source: fundraisingfox.com
Latest round on record: Series B+, November 2026, amount undisclosed.
All 3 rounds ↓Signals
Rgenta Therapeutics | 1147 days from website to first raise on record
Money raised, round by round (amounts linked to their source). Pins are dated signals; hover the icons for dates.
Funding rounds
| Date | Round | Amount | Lead | Source |
|---|---|---|---|---|
| Series B+ | undisclosed | — | sec.gov | |
| Series A | $52M | fundraisingfox.com | ||
| Seed | undisclosed | — | biospace.com |
Timeline
- X account created
- Website created
Founders and team
SX
Simon Xi Co-founder and CEOLinkedIn · source: rgentatx.comTW
Travis Wager Co-founder, President and CSOLinkedIn · source: rgentatx.comZW
Zhiping Weng Co-founderLinkedIn · source: rgentatx.com
Investors
AAstraZenecalead investor
BBoehringer Ingelheim Venture Fund
CCICClead investor
DDelos Capital
HHighlight Capital
KKaitai Capital
KKorean Investment Partners
LLegend Star
LLilly Asia Ventures
MMatrix Partners China
- TThe Leukemia & Lymphoma Society’s Therapy Acceleration Program
VVivo Capital
Companies like Rgenta Therapeutics
NNoema PharmaSeries B+ · Nov 2025
AAlzheon$100M Series B+ · Apr 2022
MMwyngil TherapeuticsSeed · Jun 2026
MMatchpoint Therapeutics$150M Series B+ · Oct 2026
MModel Medicines$4.1M · Nov 2021
WWayfinder Biosciences
Other companies backed by AstraZeneca
SSortera Bio$10.14M Pre Seed · Jun 2025HHuma Therapeutics$38M Series B+ · Sep 2024
AAsher Bio$55M Series B+ · Apr 2024
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/rgenta-therapeutics (get a free API key).